Strikingly, in a phase 1 trial of NAD-expanded allogeneic NK cells, rituximab (the monoclonal antibodies targeting CD19 molecule), and IL-2, 11 of 19 patients with relapsed or refractory non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) (NCT03019666) demonstrated complete response, suggesting that supplementation with NAD during ex vivo NK cell culture should be further investigated in detail for NHL therapy [17]. Here, CD19 is linked to non-Hodgkin lymphoma.